Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
Caitlin Costello, MD
Sagar Lonial, MD, FACP
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Integrating Bispecific Antibodies Into Clinical Practice
Efficacy Data for Bispecific Antibodies in RRMM
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
Considerations for Dosing Bispecific Antibodies
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma
Clinical Challenges With Triple-Class or Penta-Refractory MM
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.